Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3 : bibliographic reviewSGRO, C.Toxicology (Amsterdam). 1995, Vol 105, Num 1, pp 23-29, issn 0300-483XConference Paper

Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: synergism of OKT3 and interleukin-2LOTZOVA, E; SAVARY, C. A; HERBERMAN, R. B et al.Natural immunity and cell growth regulation. 1987, Vol 6, Num 5, pp 219-223, issn 0254-7600Article

Late reactions during initial OKT-3 treatmentTURNER, M. C; HOLMAN, J. M.Clinical transplantation. 1993, Vol 7, Num 1, pp 1-3, issn 0902-0063, 1Article

Adverse events associated with OKT3 immunosuppression in the prevention or treatment of allograft rejectionKREIS, H.Clinical transplantation. 1993, Vol 7, Num 4, pp 431-446, issn 0902-0063, 2Article

Antilymphocyte induction therapy in cadaver renal transplantation : A retrospective, multicenter united network for organ sharing studySHIELD, C. F; EDWARDS, E. B; DAVIES, D. B et al.Transplantation. 1997, Vol 63, Num 9, pp 1257-1263, issn 0041-1337Article

Biphasic granulocytopenia after administration of the first dose of OKT3BEMELMAN, F. J; BUYSMANN, S; YONG, S. L et al.The Journal of laboratory and clinical medicine. 1995, Vol 126, Num 6, pp 571-579, issn 0022-2143Article

Monoclonal antibodies in renal transplantation : a reviewPARLEVLIET, K. J; SCHELLEKENS, P. T. A.Transplant international. 1992, Vol 5, Num 4, pp 234-246, issn 0934-0874Article

Immunologic monitoring during OKT3 therapyCHATENOUD, L.Clinical transplantation. 1993, Vol 7, Num 4, pp 422-430, issn 0902-0063, 2Article

OKT3 treatment of acute renal allograft rejection in childrenPESCOVITZ, M. D; BREEN, N; BOOK, B. K et al.Clinical transplantation. 1992, Vol 6, Num 3, pp 184-190, issn 0902-0063, 1Article

Thromboembolic complications and dose of monoclonal OKT3 antibodyRAASVELD, M. H. M; SURACHNO, S; HACK, C. E et al.Lancet (British edition). 1992, Vol 339, Num 8805, pp 1363-1364, issn 0140-6736Article

Aseptic encephalitis and blindness complicating OKT3 therapyMARKS, W. H; PERKAL, M; BIA, M et al.Clinical transplantation. 1991, Vol 5, Num 6, pp 435-438, issn 0902-0063, 1Article

The use of antibodies in clinical cardiologyAZRIN, M. A.The American heart journal. 1992, Vol 124, Num 3, pp 753-768, issn 0002-8703Article

Laboratory monitoring of therapy with OKT3 and other murine monoclonal antibodiesCOLVIN, R. B; PREFFER, F. I.Clinics in laboratory medicine. 1991, Vol 11, Num 3, pp 693-714, issn 0272-2712Article

OKT3: immunology, production, purification, and pharmacokineticsROITT, I. V.Clinical transplantation. 1993, Vol 7, Num 4, pp 367-373, issn 0902-0063, 2Article

Immune monitoring of heart transplant patients receiving either one or two cycles of OKT3 prophylaxis. Induced anti-idiotypic and anti-isotypic anti-OKT3 antibodies do not prohibit depletion of peripheral T cells due to second OKT3 treatmentHESSE, C. J; HEYSE, P; STOLK, B. J. M et al.Clinical transplantation. 1991, Vol 5, Num 6, pp 446-455, issn 0902-0063, 1Article

Muromonab-CD3 (Orthoclone OKT3®), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantationBENEKLI, M; HAHN, T; WILLIAMS, B. T et al.Bone marrow transplantation (Basingstoke). 2006, Vol 38, Num 5, pp 365-370, issn 0268-3369, 6 p.Article

The fate of renal allografts treated with OKT3 for steroid-resistant rejectionVERONESE, F. V; GONCALVES, L. F; VILARINHO, L. L et al.Transplantation proceedings. 1999, Vol 31, Num 7, pp 3016-3018, issn 0041-1345Conference Paper

The impact of cytolytic therapy on Bronchiolitis obliterans syndromeDATE, H; LYNCH, J. P; SUNDARESAN, S et al.The Journal of heart and lung transplantation. 1998, Vol 17, Num 9, pp 869-875, issn 1053-2498Article

Biological effects and fate of a soluble, dimeric, 80-kDa tumor necrosis factor receptor in renal transplant recipients who receive OKT3 therapyWEE, S; PASCUAL, M; EASON, J. D et al.Transplantation. 1997, Vol 63, Num 4, pp 570-577, issn 0041-1337Article

Treatment of renal allograft rejection with T10B9.1A31 or OKT3 : Final analysis of a phase II clinical trialWAID, T. H; LUCAS, B. A; THOMPSON, J. S et al.Transplantation. 1997, Vol 64, Num 2, pp 274-281, issn 0041-1337Article

Increased expression of ICAM-1 and VCAM-1 in the skin after administration of the first dose of OKT3TEN BERGE, R. J. M; BUYSMANN, S; VAN DIEPEN, F. N. J et al.Transplantation proceedings. 1997, Vol 29, Num 1-2, pp 325-327, issn 0041-1345Conference Paper

Tacrolimus (FK506) proves superior to OKT3 for treating episodes of persistent rejection following intrathoracic transplantationMEISER, B. M; ÜBERFUHR, P; SCHULZE, C et al.Transplantation proceedings. 1997, Vol 29, Num 1-2, pp 605-606, issn 0041-1345Conference Paper

Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation : A plea for multicenter immunosuppressive trialsROSS, D. J; JORDAN, S. C; NATHAN, S. D et al.Chest. 1996, Vol 109, Num 4, pp 870-873, issn 0012-3692Article

OKT3-induced nephrotoxicity is associated with release of group II secretory phospholipase A₂WEVER, P. C; ROEST, R. W; WOLBINK-KAMP, A. M et al.European journal of clinical investigation. 1996, Vol 26, Num 10, pp 873-878, issn 0014-2972Article

The IgE humoral response in OKT3-treated patients : Incidence and fine specificityABRAMOWICZ, D; CRUSIAUX, A; NIAUDET, P et al.Transplantation. 1996, Vol 61, Num 4, pp 577-581, issn 0041-1337Article